Pascal Deschatelets, PhD


Dr. Deschatelets is the Chief Operating Officer of Apellis Pharmaceuticals, a company he founded in Louisville in 2009.  Apellis is focused on developing a new class of peptide drugs to the market to address a broad range of chronic inflammatory conditions, with an initial emphasis on asthma, chronic obstructive pulmonary disease (COPD), and Paroxysmal Nocturnal Hemoglobinuria.  Prior to Apellis, Dr. Deschatelets founded Potentia in 2001, also acting as its Chief Operating Officer until the acquisition of its ocular drug development program by Alcon in 2009.  In addition to overseeing the day-to-day activities of these companies and managing external contracts and collaborations, he is actively involved in overseeing their research and development efforts and supporting all the fundraising and business development work.  Scientifically, Dr. Deschatelets has been engaged in state-of-the-art research in the areas of chemistry, nanotechnology, diagnostic and biosensing, and drug development for the last 20 years. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.